Oxford Biomedica Launches Next Generation Lentiviral Vector System: TetraVecta™

After years of development and understanding of specific industry challenges, Oxford Biomedica launched the TetraVecta^TM system, already demonstrating success in pilot projects and being implemented to support the development of more complex advanced therapies.

The TetraVectaTM system greatly enhances the development and manufacture of safer and more effective lentiviral vector-based therapies to overcome crucial barriers in the therapeutic development space. The TetraVectaTM system has validated its versatile potential by supporting the creation of high-titre stable producer cell lines for prior unattainable payloads such as Chimeric Antigen Receptor (CAR) constructs for CAR-T therapy.

How are you enjoying this news article? Let us know your thoughts, here >>

Kyriacos Mitrophanous, Chief Scientific Officer of Oxford Biomedica, stated:

 “The launch of The TetraVecta^TM system demonstrates our commitment to investing in innovation in the cell and gene therapy field. This next generation lentiviral vector system empowers our clients to overcome previous-generation vector limitations and develop life-saving treatments. By addressing critical industry challenges and streamlining the development process, we are enabling our clients to shape the future of gene therapy.”

Oxford Biomedica is a quality and innovation-led viral vector CDMO – one of the original pioneers in cell and gene therapy. This cutting-edge new technology paves the way for effective and efficient manufacturing and will be able to support Oxford Biomedica’s clients in delivering their life-changing treatments to patients. The features of the TetraVecta^TM system can also be used to elevate the development and incorporation of in vivo gene therapies by means of intravenous injection or to a specific organ.

“The TetraVecta^TM system has the potential to make a lasting impact on the industry. Our ultimate aim is to constantly provide clients with high quality, cutting-edge technology, supporting their efforts to bring transformative therapies to patients in need,” commented Mitrophanous.

Source: Oxford Biomedica Press Release

While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.